BEGIN:VCALENDAR VERSION:2.0 PRODID:icalendar-ruby CALSCALE:GREGORIAN BEGIN:VEVENT DTSTAMP:20240329T104547Z UID:a4fd3953-1a00-40e5-904b-daf39e3bdf31 DTSTART:20210413T073000 DTEND:20210414T073000 CLASS:PRIVATE DESCRIPTION:
 \;
\n\n*** L
IMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! ***
\nREGISTER TODAY!
 \;
\n\n \;
\n\nGT Cbio is proud to present the Stem Cell Summit 2021\, to be held in San Die go\, CA. The Stem Cell Summit provides information on cutting-edge develop ments in all areas of stem cell research from bench to bedside\, including the biology\, medicine\, applications\, regulations\, product development \, and the commercialization of stem cells. This summit comprises of prese ntations\, panels and round-table discussions to highlight pre-clinical an d clinical studies in regenerative medicine\, immunotherapy\, stem cell re programming\, cell therapy in diabetes\, regulatory policies regarding ste m cell research\, manufacturing and other relevant topics.
\n\n
\nStem Cell Summit 2021 \;includes two back-to-back
conferences including joint plenary session:
\nCon
ference 1: \;15th Stem Cell Research &\; Regenerative Medi
cine
Advances in Adult &\; Pluripotent Stem Cel l Research
\nRevolution in Immunotherapy
\nWhat&rsquo\;s in the Pipeline: Pre-clinical &\; Clinical S trategies
\nJoint: Plenary Session
\n\nWhere do We Stand with Cell Therapy in Diabetes?< /p>\n
Conference 2: \;7th Stem Cel l Product Development &\; Commercialization
\n\nReg ulatory Challenges in Cell Therapy
\nFunding and Par tnering
\nStem Cells for Drug Discovery &\; Disea se Modeling
\nManufacturing and Scalable Processes p>\n
Biotech Showcase: Emerging Pipelines
\nCommercialization: Creating Sustainable Business Models
\n li>\n \;
\n\n \;
\n\nDay 1 - Thursday\, April 12\, 2021
\n\n7:30 Continental Breakfast &\; Registration
\n8:15 Opening Rema
rks by GTCbio
\nOpening Keynote Session &ndash\; Historical Perspecti
ve and State of the Science &\; Industry
KEYNOTE
\n8:30S
tem Cells for Diabetics
\nDouglas Melton Douglas Melton \;
\
nProfessor
\nHarvard University
\n
\nAbstract: The advances
and remaining challenges...Read More \;
\nKEYNOTE
\n9:15Cli
nical and Commercial Application of Scaled Human Stem Cell Derivates
\nHans Keirstead Hans Keirstead \;
\nChief Executive Officer
\nAIVITA Biomedical
\n
\nAbstract: AIVITA Biomedical has develo
ped propr...Read More \;
\n10:00 Morning Networking Break
\n
Stem Cell Product Development &\; Commercialization
\nStem Cells f
or Drug Discovery &\; Disease Modeling \;
\nModerator: Scott O
lson\, University of Texas \;
\n10:30Stem Cell Derived Human-on-a
-chip Systems for Use in Efficacy and Toxicological Investigations in Pre-
clinical Drug Discovery
\nJames Hickman James Hickman \;
\nP
rofessor\, NanoScience Technology Center
\nUniversity of Central Flor
ida
\n
\nAbstract: The utilization of human-on-a-chip or...Read
More \;
\nStem Cell Research &\; Regenerative Medicine
\n
Advances in Adult Stem Cell Research
10:30Addressing Age-related
Macular Degeneration with Adult Retinal Pigment Epithelial Stem Cells
\nSally Temple Sally Temple \;
\nScientific Director
\nNeu
ral Stem Cell Institute
\n
\nAbstract: The retinal pigment epith
elium (RPE) ...Read More \;
\n10:55Ensuring the quality of stem c
ell derived models for toxicity testing. In: Validation of Alternative Met
hods for Toxicity Testing.
\nGlyn Stacey Glyn Stacey \;
\nHe
ad of Division
\nNational Institute for Biological Standards and Cont
rol
\n
\nAbstract: The development of in vitro assays fo...Read
More \;
\n10:55
\nDouglas Losordo Douglas Losordo \;
\nChief Medical Officer\, Senior Vice President of Clinical\, Medical &a
mp\; Regulatory Affairs
\nCaladrius Biosciences
\n
\n11:20M
edical Gas Therapy for SCI: Roles of Adult Neurogenesis
\nYang (Ted)
D Teng Yang (Ted) D Teng \;
\nDirector\, Laboratory of SCI\, Stem
Cell &\; Neurofacilitation Research PM&\;R and Neurosurgery
\n
Harvard University and Spaulding Rehabilitation Hospital
\n
\nAb
stract: We previously reported that non-toxic...Read More \;
\n11
:20Bone Marrow Cells for Heart Repair: Cumulative Clinical Evidence and In
sights
\nBuddhadeb Dawn Buddhadeb Dawn \;
\nDirector\, Midwe
st Stem Cell Therapy Center \;
\nUniversity of Kansas Medical Cen
ter
\n
\nAbstract: Numerous clinical trials of bone marr...Read
More \;
\n11:45
\nTBA (To Be Announced) TBA (To Be Announced
)
\n11:45
\nSilviu Itescu Silviu Itescu \;
\
nChief Executive Officer &\; Managing Director
\nMesoblast
\n
\n12:10 Lunch on Your Own
\nStem Cell Product Development &\
; Commercialization
\nPartnering between Industry\, Academia\, and CR
Os to Advance Research
1:45Cross-institutional Collaboration in
Academia and Industry
\nBrock Reeve Brock Reeve \;
\nExecuti
ve Director
\nHarvard Stem Cell Institute
\n
\nStem Cell Re
search &\; Regenerative Medicine
\nAdvances in Pluripotent Stem Ce
ll Research
1:45
\nMahendra Rao Mahendra Rao \;
\n
Vice President for Regenerative Medicine
\nNew York Stem Cell Foundat
ion
\n
\n2:10
\nAnthony Ting Anthony Ting \;
\nVic
e President
\nAthersys
\n
\n2:10
\nKristin Baldwin Kri
stin Baldwin \;
\nProfessor\, Investigator\, Dorris Neuroscience
Center\, Department of Neuroscience California Campus
\nScripps Insti
tute
\n
\n2:35Panel Discussion: Partnering between Industry\, Ac
ademia\, and CROs to Advance Research
\nPanelist:Alain Vertè\;s
Alain Vertè\;s \;
\nManaging Director
\nNxR Biotechno
logies GmbH
\nPanelist:TBA (To Be Announced) TBA (To Be Announced)
Panelist:TBA (To Be Announced) TBA (To Be Announced)
\n\n2:3
5
\nKevin Eggan Kevin Eggan \;
\nProfessor in the Department
of Stem Cell and Regenerative Biology
\nHarvard University
\n\n3:00
\nTBA (To Be Announced) TBA (To Be Announced)
\n3:25 Afternoon Networking Break
\nRound Table Sessions \;\n5:15 Networking Reception &\; Poster Session
\nDay 1 Day 2\n \;
 \;
\n\nDay - 2 Friday\, April 1 3\, 2021
\n\n
\n7:15 Breakfast with Mentors from Acade
mia &\; Industry (RSVP Only)
\n7:30 Continental Breakfast for All
Attendees
\nStem Cell Product Development &\; Commercialization
\nManufacturing and Scalable Processes for Cell Therapy
8:30<
br />\nKaty Spink Katy Spink \;
\nManaging Partner
\nDark Ho
rse Consulting
\n
\nStem Cell Research &\; Regenerative Medic
ine
\nTranslation to the Clinic: What&rsquo\;s in the Pipeline
8:30Mesenchymal Stromal Cells &ndash\; Pre-clinical Science\, Clinical
Development and Pathway to Marketing Approval
\nJacques Galipeau Jac
ques Galipeau \;
\nDon and Marilyn Anderson Professor in Oncology
\; Assistant Dean for Therapeutics Discovery and Development\; Director\,
Program for Advanced Cell Therapy
\nUniversity of Wisconsin in Madiso
n
\n
\nAbstract: Mesenchymal Stromal Cells have been t...Read Mo
re \;
\n8:55
\nEmily Titus Emily Titus \;
\nDirecto
r\, Technology Development
\nCentre for Commercialization of Regenera
tive Medicine (CCRM)
\n
\n8:55
\nDeborah Ascheim Deborah As
cheim \;
\nChief Medical Officer \;
\nCapricor
\n\n9:20Efficient Scale Up/Scale Out of Cell Therapies
\nKevin Murr
ay Kevin Murray \;
\nVice President\, Global Sales
\nBioSphe
rix Medical
\n
\nAbstract: The first cell therapies have finally
...Read More \;
\n9:20Clinical Translation of Pluripotent Cell-De
rived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy
\nBob Va
lamehr Bob Valamehr \;
\nVice President\, Cancer Immunotherapy &a
mp\; Reprogramming Biology
\nFate Therapeutics Inc.
\n
\nAb
stract: The unique attributes of a combinator...Read More \;
\n9:
45Cell Therapy Manufacturing\, a Continuous Development
\nWilfried Da
lemans Wilfried Dalemans \;
\nChief Technical Officer
\nTige
nix
\n
\nAbstract: Cell therapy manufacturing starts alr...Read
More \;
\n9:45Clinical Trials in TBI: Preventing the Next Failure
\nScott Olson Scott Olson \;
\nAssistant Professor\, Progra
m in Regenerative Medicine \;
\nUniversity of Texas
\n
\nAbstract: Clinical trials using small molecules...Read More \;
\n10:10 Morning Networking Break
\nStem Cell Product Development &
\; Commercialization
\nFunding &\; Commercialization of Cell Thera
py
10:40Accelerating Stem Cell Therapy Development
\nGil Sa
mbrano Gil Sambrano \;
\nVice President of Portfolio Development
and Review
\nCalifornia Institute for Regenerative Medicine
\n\nAbstract: The California Institute for Regenera...Read More \;\nStem Cell Research &\; Regenerative Medicine
\nRevolution in
Immunotherapy
10:40
\nKhalid Shah Khalid Shah \;
\nDirector Center for Stem Cell Therapeutics and Imaging
\nHarvard Me
dical School
\n
\n11:05
\nPatrick Keenan Patrick Keenan&nbs
p\;
\nManaging Director
\nPrevail Partners
\n
\n11:05<
br />\nRichard Morgan Richard Morgan \;
\nVice President\, Immuno
therapy
\nBluebird Bio
\n
\n11:30Panel: Funding &\; Comm
ercialization of Cell Therapy
\nPanelist:Gail Naughton Gail Naughton&
nbsp\;
\nChief Executive Officer
\nHistogen
\nPanelist:Mich
ael May Michael May \;
\nPresident &\; CEO
\nCentre for C
ommercialization of Regenerative Medicine (CCRM)
\nPanelist:Gregory B
onfiglio Gregory Bonfiglio \;
\nManaging Partner
\nProteus V
enture Partners
\n11:30IMPACT: Re-engineered CAR19 T cells have Poten
t Activity Against Hematologic and Solid Tumors
\nPaul Rennert Paul R
ennert \;
\nPresident &\; CSO
\nAleta Biotherapeutics
\n
\nAbstract: CAR-CD19 T cell therapeutics are appr...Read More&nb
sp\;
\n11:55
\nMyLinh Duong MyLinh Duong \;
\nSenior Sc
ientist
\nBellicum Pharmaceuticalsss
\n
\nLunch Session: Re
gulatory Challenges in Cell Therapy
12:30Japanese Policy for Reg
ulatory Science of Stem Cell Therapies
\nToshio Miyata Toshio Miyata&
nbsp\;
\nProfessor\, Office for Industry-University Co-Creation
\nOsaka University
\n
\nAbstract: Japan government fosters pharm
aceutic...Read More \;
\n12:55Global Regulatory Policy and Projec
t Update
\nMelody Eble Melody Eble \;
\nDirector\, Global Re
gulatory Affairs
\nJanssen Research &\; Development\, LLC
\n<
br />\nAbstract: This session will describe select\, re...Read More \;
\nAward Ceremony &\; Closing Keynote Lunch Session
KEYN
OTE
\n1:20
\nEvan Snyder Evan Y. Snyder \;
\nProfessor
and Director\, Program in Stem Cell &\; Regenerative Biology
\nSan
ford-Burnham Medical Research Institute
\n
\nKEYNOTE
\n2:05
A Glimpse of the Next 10 Years for Pluripotent Stem Cell-based Therapies\nErin Kimbrel Erin Kimbrel \;
\nSenior Director of Developme
nt
\nAstellas Institute for Regenerative Medicine
\n
\nKeyn
ote Panel Discussion \;
\nModerator: Erin Kimbrel\, Astellas Inst
itute for Regenerative Medicine \;
\n2:20
\nModerator:
\nErin Kimbrel Erin Kimbrel \;
\nSenior Director of Development\nAstellas Institute for Regenerative Medicine
\nPanelist:
\
nEvan Snyder Evan Y. Snyder \;
\nProfessor and Director\, Program
in Stem Cell &\; Regenerative Biology
\nSanford-Burnham Medical R
esearch Institute
\nPanelist:
\nHans Keirstead Hans Keirstead&nb
sp\;
\nChief Executive Officer
\nAIVITA Biomedical
\n3:05 S
ummit Concludes
 \;
\n\n \;
\n\n \;
\ n\n \;
\n\nPlease contact the event man
ager Marilyn (marilyn.b.turner(at)nyeventslist.com ) below for: \;
\n- Multiple participant discounts \;
\n- Price quotations or v
isa invitation letters \;
\n- Payment by alternate channels (PayP
al\, check\, Western Union\, wire transfers etc) \;
\n- Event spo
nsorship \;
\n
\nNO REFUNDS ALLOWED ON REGISTRATIONS \;<
br />\nPrices may go up any time. Service fees included in pricing. \;
\n-----------------------------------------------------------------&
nbsp\;
\nThis event is brought to you by: \;
\nGlobal Techno
logy Community LLC - NewYorkEventsList \;
\nhttp://www.NyEventsLi
st.com \;
\nhttp://www.BostonEventsList.com \;
\nhttp://
www.SFBayEventsList.com \;
\n------------------------------------
-----------------------------
\nMYL170816CEV \;MAR170927UPT MYL17
1025UPD
CHA171109UPT MAR20211124REV VIO180228UP D
\n\nMYL180302UPD \;JOA180315CEV
\ n SUMMARY:Stem Cell Summit (GTC) S BEGIN:VALARM ACTION:DISPLAY TRIGGER:-PT1H SUMMARY:Stem Cell Summit (GTC) S END:VALARM END:VEVENT END:VCALENDAR